IntegraGen today announces its sales, unaudited, for the first half of 2020. Unaudited sales for the first half amounted to €4,706K, up 13% on the first half of 2019 and 15% on a like-for-like basis, as the "diagnostics" business was sold at the beginning of 2020. Sales growth stems from the increase in all sequencing activities, in particular the SeqOIA platform (+33%), activity relating to outsourced platforms (+18%), and, finally, services dedicated to research laboratories and teams in charge of clinical research (+9%).
July 09, 2020
Share :
Leave a Reply